These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26441082)

  • 1. Clinical trials: Early phase clinical trials-are dose expansion cohorts needed?
    Iasonos A; O'Quigley J
    Nat Rev Clin Oncol; 2015 Nov; 12(11):626-8. PubMed ID: 26441082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB].
    Ezzalfani M; Dugué A; Mollevi C; Pulido M; Bonnetain F; Filleron T; Gal J; Gauthier M; Le Deley MC; Le Tourneau C; Médioni J; Nguyen JM; Chabaud S; Teixeira L; Thivat E; You B; Kramar A; Paoletti X
    Bull Cancer; 2015 Jan; 102(1):73-82. PubMed ID: 25609488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential monitoring of Phase I dose expansion cohorts.
    Iasonos A; O'Quigley J
    Stat Med; 2017 Jan; 36(2):204-214. PubMed ID: 26854196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical controversies in clinical research: building the bridge to phase II-efficacy estimation in dose-expansion cohorts.
    Boonstra PS; Braun TM; Taylor JMG; Kidwell KM; Bellile EL; Daignault S; Zhao L; Griffith KA; Lawrence TS; Kalemkerian GP; Schipper MJ
    Ann Oncol; 2017 Jul; 28(7):1427-1435. PubMed ID: 28200082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interval estimates of the probability of toxicity at the maximum tolerated dose for small samples.
    Natarajan L; O'Quigley J
    Stat Med; 2003 Jun; 22(11):1829-36. PubMed ID: 12754718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A two-dimensional search algorithm for dose-finding trials of two agents.
    Lee BL; Fan SK
    J Biopharm Stat; 2012; 22(4):802-18. PubMed ID: 22651116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose selection in phase I studies: why we should always go for the most effective.
    Haines IE
    J Clin Oncol; 2008 Jul; 26(21):3650-2; author reply 3652-3. PubMed ID: 18640947
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose selection in phase I studies: why we should always go for the top.
    Sleijfer S; Wiemer E
    J Clin Oncol; 2008 Apr; 26(10):1576-8. PubMed ID: 18332465
    [No Abstract]   [Full Text] [Related]  

  • 11. Review: new biological insights in early clinical studies.
    Maur M; Sessa C
    Hematol Oncol; 2007 Jun; 25(2):53-7. PubMed ID: 17351979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
    Hirakawa A
    Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design issues in dose-finding Phase I trials for combinations of two agents.
    Fan SK; Venook AP; Lu Y
    J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-sample behavior of novel phase I cancer trial designs.
    Oron AP; Hoff PD
    Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In defense of Phase I trials.
    Lévy V; Chevret S
    Hematol J; 2000; 1(6):427. PubMed ID: 11920224
    [No Abstract]   [Full Text] [Related]  

  • 17. Early phase cancer clinical trials: design, ethics and future directions.
    Coupe N; Gupta A; Lord SR
    Br J Hosp Med (Lond); 2015 Jul; 76(7):409-13. PubMed ID: 26140560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
    Messer K; Natarajan L; Ball ED; Lane TA
    Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.
    Manji A; Brana I; Amir E; Tomlinson G; Tannock IF; Bedard PL; Oza A; Siu LL; Razak AR
    J Clin Oncol; 2013 Nov; 31(33):4260-7. PubMed ID: 24127441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical justification of expansion cohorts in phase 1 cancer trials.
    Mokdad AA; Xie XJ; Zhu H; Gerber DE; Heitjan DF
    Cancer; 2018 Aug; 124(16):3339-3345. PubMed ID: 29975406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.